Epigenetic mechanisms in Parkinson's disease

Journal of the Neurological Sciences

Volumn 349, Issue 1-2, 2015, Pages 3-9

  Feng, Ya ^a   Jankovic, Joseph ^b   Wu, Yun Cheng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

DNA methylation; Epigenetic modification; Histone acetylation; Non coding; Parkinson's disease; RNAs

Indexed keywords

BUTYRIC ACID; CYANOCOBALAMIN; CYTOCHROME P450; CYTOCHROME P450 2E1; DNA; HISTONE; HOMOCYSTEINE; PROTEIN; PROTEIN PINK1; S ADENOSYLMETHIONINE; TAU PROTEIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VORINOSTAT;

AMINO ACID BLOOD LEVEL; CARBON METABOLISM; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DNA METHYLATION; EPIGENETICS; FOLIC ACID BLOOD LEVEL; GENE; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; FEMALE; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; MALE; RISK FACTOR;

DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HISTONES; HUMANS; MALE; PARKINSON DISEASE; RISK FACTORS; RNA, UNTRANSLATED;

EID: 84923842291     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.12.017     Document Type: Review

References (78)

1. M. Ozansoy, and A.N. Basak The central theme of Parkinson's disease: alpha-synuclein Mol Neurobiol 47 2013 460 465
2. Y. Wu, W. Le, and J. Jankovic Preclinical biomarkers of Parkinson disease Arch Neurol 68 2011 22 30
3. L.V. Kalia, S.K. Kalia, P.J. McLean, A.M. Lozano, and A.E. Lang alpha-Synuclein oligomers and clinical implications for Parkinson disease Ann Neurol 73 2013 155 169
4. T.F. Jiang, and S.D. Chen Dysfunction of two lysosome degradation pathways of alpha-synuclein in Parkinson's disease: potential therapeutic targets? Neurosci Bull 28 2012 649 657
5. M. Oliveras-Salva, A. Van der Perren, N. Casadei, S. Stroobants, S. Nuber, and R. D'Hooge rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration Mol Neurodegener 8 2013 44
6. P. Desplats, P. Patel, K. Kosberg, M. Mante, C. Patrick, and E. Rockenstein Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease Mol Neurodegener 7 2012 49
7. S.C. Marques, C.R. Oliveira, C.M. Pereira, and T.F. Outeiro Epigenetics in neurodegeneration: a new layer of complexity Prog Neuropsychopharmacol Biol Psychiatry 35 2011 348 355
8. A. Portela, and M. Esteller Epigenetic modifications and human disease Nat Biotechnol 28 2010 1057 1068
9. N. Ammal Kaidery, S. Tarannum, and B. Thomas Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalities Neurotherapeutics 10 2013 698 708
10. J.J. Day, and J.D. Sweatt DNA methylation and memory formation Nat Neurosci 13 2010 1319 1323
11. J.U. Guo, D.K. Ma, H. Mo, M.P. Ball, M.H. Jang, and M.A. Bonaguidi Neuronal activity modifies the DNA methylation landscape in the adult brain Nat Neurosci 14 2011 1345 1351
12. I.A. Qureshi, and M.F. Mehler Advances in epigenetics and epigenomics for neurodegenerative diseases Curr Neurol Neurosci Rep 11 2011 464 473
13. C.J. Klein, and E.E. Benarroch Epigenetic regulation: basic concepts and relevance to neurologic disease Neurology 82 2014 1833 1840
14. X.R. Long, Y. He, C. Huang, and J. Li MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis Int J Oncol 44 2014 1915 1922
15. B.L. Wienholz, M.S. Kareta, A.H. Moarefi, C.A. Gordon, P.A. Ginno, and F. Chedin DNMT3L modulates significant and distinct flanking sequence preference for DNA methylation by DNMT3A and DNMT3B in vivo PLoS Genet 6 2010 e1001106
16. J.X. Cao, H.P. Zhang, and L.X. Du Influence of environmental factors on DNA methylation Yi Chuan 35 2013 839 846
17. J.M. Laffita-Mesa, and P. Bauer Epigenetic heredity (deoxyribonucleic acid methylation): clinical context in neurodegenerative disorders and ATXN2 gene Med Clin (Barc) 143 2014 360 365
18. M.V. Dhobale, H.R. Pisal, S.S. Mehendale, and S.R. Joshi Differential expression of human placental neurotrophic factors in preterm and term deliveries Int J Dev Neurosci 31 2013 719 723
19. F. Coppede One-carbon metabolism and Alzheimer's disease: focus on epigenetics Curr Genomics 11 2010 246 260
20. W. Duan, B. Ladenheim, R.G. Cutler, I.I. Kruman, J.L. Cadet, and M.P. Mattson Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease J Neurochem 80 2002 101 110
21. R. Ceravolo, G. Cossu, M. Bandettini di Poggio, L. Santoro, P. Barone, and M. Zibetti Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study Mov Disord 28 2013 1391 1397
22. K. Szadejko, K. Szabat, A. Ludwichowska, and J. Sławek Homocysteine and its role in pathogenesis of Parkinson's disease and other neurodegenerative disorders Przegl Lek 70 2012 443 447
23. S. Sapkota, M. Gee, J. Sabino, D. Emery, and R. Camicioli Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease Mov Disord 29 2014 368 374
24. A. Jara-Prado, A. Ortega-Vazquez, L. Martinez-Ruano, C. Rios, and A. Santamaria Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor blockade, antioxidant treatment, and nitric oxide synthase inhibition Neurotox Res 5 2003 237 243
25. K.S. McCully Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation Ann Clin Lab Sci 39 2009 219 232
26. I.I. Kruman, C. Culmsee, S.L. Chan, Y. Kruman, Z. Guo, and L. Penix Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity J Neurosci 20 2000 6920 6926
27. C.D. Marsden Parkinson's disease J Neurol Neurosurg Psychiatry 57 1994 672 681
28. S. Searles Nielsen, H. Checkoway, R.A. Butler, H.H. Nelson, F.M. Farin, and W.T. Longstreth Jr. LINE-1 DNA methylation, smoking and risk of Parkinson's disease J Park Dis 2 2012 303 308
29. M. van der Mark, P.C. Nijssen, J. Vlaanderen, A. Huss, W.M. Mulleners, and A.M. Sas A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking PLoS One 9 2014 e95297
30. A. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, and J. Kachergus α-Synuclein locus triplication causes Parkinson's disease Science 302 2003 841
31. T.L. Edwards, W.K. Scott, C. Almonte, A. Burt, E.H. Powell, and G.W. Beecham Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease Ann Hum Genet 74 2010 97 109
32. S.X. Ai, Q. Xu, Y.C. Hu, C.Y. Song, J.F. Guo, and L. Shen Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease J Neurol Sci 337 2014 123 128
33. L. Matsumoto, H. Takuma, A. Tamaoka, H. Kurisaki, H. Date, and S. Tsuji CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease PLoS One 5 2010 e15522
34. Y.Y. Tan, L. Wu, Z.B. Zhao, Y. Wang, Q. Xiao, and J. Liu Methylation of alpha-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients Parkinsonism Relat Disord 20 2014 308 313
35. Y. Song, H. Ding, J. Yang, Q. Lin, J. Xue, and Y. Zhang Pyrosequencing analysis of SNCA methylation levels in leukocytes from Parkinson's disease patients Neurosci Lett 569 2014 85 88
36. P. Desplats, B. Spencer, E. Coffee, P. Patel, S. Michael, and C. Patrick Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases J Biol Chem 286 2011 9031 9037
37. N. Pankratz, J.B. Wilk, J.C. Latourelle, A.L. DeStefano, C. Halter, and E.W. Pugh Genomewide association study for susceptibility genes contributing to familial Parkinson disease Hum Genet 124 2009 593 605
38. K.G. Coupland, G.D. Mellick, P.A. Silburn, K. Mather, N.J. Armstrong, and P.S. Sachdev DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E In Vitro Mov Disord 29 2014 1606 1614
39. A.G. Riedl, P.M. Watts, P. Jenner, and C.D. Marsden P450 enzymes and Parkinson's disease: the story so far Mov Disord 13 1998 212 220
40. O. Kaut, I. Schmitt, and U. Wullner Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1 Neurogenetics 13 2012 87 91
41. H.C. Pieper, B.O. Evert, O. Kaut, P.F. Riederer, A. Waha, and U. Wullner Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability Neurobiol Dis 32 2008 521 527
42. T. Kouzarides Chromatin modifications and their function Cell 128 2007 693 705
43. Y. Wang, X. Miao, Y. Liu, F. Li, Q. Liu, and J. Sun Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases Oxid Med Cell Longev 2014 2014 641979
44. D.R. Grayson, M. Kundakovic, and R.P. Sharma Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol 77 2010 126 135
45. T.F. Outeiro, E. Kontopoulos, S.M. Altmann, I. Kufareva, K.E. Strathearn, and A.M. Amore Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease Science 317 2007 516 519
46. I.F. Harrison, and D.T. Dexter Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease? Pharmacol Ther 140 2013 34 52
47. A. Siddiqui, S.J. Chinta, J.K. Mallajosyula, S. Rajagopolan, I. Hanson, and A. Rane Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease Free Radic Biol Med 53 2012 993 1003
48. A. Kanthasamy, H. Jin, V. Anantharam, G. Sondarva, V. Rangasamy, and A. Rana Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration Neurotoxicology 33 2012 833 837
49. C. Song, A. Kanthasamy, H. Jin, V. Anantharam, and A. Kanthasamy Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration Neurotoxicology 32 2011 586 595
50. C. Song, A. Kanthasamy, V. Anantharam, F. Sun, and A.G. Kanthasamy Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration Mol Pharmacol 77 2010 621 632
51. A. Berthier, J. Jimenez-Sainz, and R. Pulido PINK1 regulates histone H3 trimethylation and gene expression by interaction with the polycomb protein EED/WAIT1 Proc Natl Acad Sci U S A 110 2013 14729 14734
52. F. Coppede Genetics and epigenetics of Parkinson's disease ScientificWorldJournal 2012 2012 489830
53. R. Johnson, W. Noble, G.G. Tartaglia, and N.J. Buckley Neurodegeneration as an RNA disorder Prog Neurobiol 99 2012 293 315
54. E.A. Kozina, G.R. Khakimova, V.G. Khaindrava, V.G. Kucheryanu, N.E. Vorobyeva, and A.N. Krasnov Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism J Neurol Sci 340 2014 198 207
55. J. Kim, K. Inoue, J. Ishii, W.B. Vanti, S.V. Voronov, and E. Murchison A MicroRNA feedback circuit in midbrain dopamine neurons Science 317 2007 1220 1224
56. J. Jankovic, S. Chen, and W.D. Le The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease Prog Neurobiol 77 2005 128 138
57. N. Kanagaraj, H. Beiping, S.T. Dheen, and S.S. Tay Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins Neuroscience 272 2014 167 179
58. W. Kim, Y. Lee, N.D. McKenna, M. Yi, F. Simunovic, and Y. Wang miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling Neurobiol Aging 35 2014 1712 1721
59. E. Junn, K.W. Lee, B.S. Jeong, T.W. Chan, J.Y. Im, and M.M. Mouradian Repression of alpha-synuclein expression and toxicity by microRNA-7 Proc Natl Acad Sci U S A 106 2009 13052 13057
60. E. Doxakis Post-transcriptional regulation of α-synuclein expression by mir-7 and mir-153 J Biol Chem 285 2010 12726 12734
61. L. Alvarez-Erviti, Y. Seow, A.H. Schapira, M. Rodriguez-Oroz, J. Obeso, and J. Cooper Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease Cell Death Dis 4 2013 e545
62. Y. Saito, and H. Saito MicroRNAs in cancers and neurodegenerative disorders Front Genet 3 2012 194
63. R. Xiong, Z. Wang, Z. Zhao, H. Li, W. Chen, and B. Zhang MicroRNA-494 reduces DJ-1 expression and exacerbates neurodegeneration Neurobiol Aging 35 2014 705 714
64. L. Alvarez-Erviti, Y. Seow, A.H. Schapira, M.C. Rodriguez-Oroz, J.A. Obeso, and J.M. Cooper Influence of microRNA deregulation on chaperone-mediated autophagy and alpha-synuclein pathology in Parkinson's disease Cell Death Dis 4 2013 e545
65. E. Masliah, W. Dumaop, D. Galasko, and P. Desplats Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes Epigenetics 8 2013 1030 1038
66. R. Margis, and C.R. Rieder Identification of blood microRNAs associated to Parkinson's disease J Biotechnol 152 2011 96 101
67. Z. Konsoula, and F.A. Barile Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders J Pharmacol Toxicol Methods 66 2012 215 220
68. Z. Xu, H. Li, and P. Jin Epigenetics-based therapeutics for neurodegenerative disorders Curr Transl Geriatr Exp Gerontol Rep 1 2012 229 236
69. P. Narayan, and M. Dragunow Pharmacology of epigenetics in brain disorders Br J Pharmacol 159 2010 285 303
70. Y. Wang, X. Wang, R. Li, Z.F. Yang, Y.Z. Wang, and X.L. Gong A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, exacerbates neurotoxicity and upregulates Parkinson's disease-related genes in dopaminergic neurons CNS Neurosci Ther 19 2013 183 190
71. N. Kato, H. Yamamoto, Y. Adachi, H. Ohashi, H. Taniguchi, and H. Suzuki Cancer detection by ubiquitin carboxyl-terminal esterase L1 methylation in pancreatobiliary fluids World J Gastroenterol 19 2013 1718 1727
72. T. Abel, and R.S. Zukin Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders Curr Opin Pharmacol 8 2008 57 64
73. M. Zhu, W.W. Li, and C.Z. Lu Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP + CNS Neurosci Ther 20 2014 308 316
74. S.K. Kidd, and J.S. Schneider Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease Neuroscience 194 2011 189 194
75. G.S. Peng, G. Li, N.S. Tzeng, P.S. Chen, D.M. Chuang, and Y.D. Hsu Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia Brain Res Mol Brain Res 134 2005 162 169
76. A.P. Nicholas, F.D. Lubin, P.J. Hallett, P. Vattem, P. Ravenscroft, and E. Bezard Striatal histone modifications in models of levodopa-induced dyskinesia J Neurochem 106 2008 486 494
77. S. Darmopil, A.B. Martin, I.R. De Diego, S. Ares, and R. Moratalla Genetic inactivation of dopamine D1 but not D2 receptors inhibits l-DOPA-induced dyskinesia and histone activation Biol Psychiatry 66 2009 603 613
78. T. Palm, L. Bahnassawy, and J. Schwamborn MiRNAs and neural stem cells: a team to treat Parkinson's disease? RNA Biol 9 2012 720 730